Amarin Corp Plcuk (AMRN) EBIT (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported EBIT of -$11.3 million for Q1 2026, up 32.35% year-over-year from -$8.6 million in Q1 2025, and down 132.54% quarter-over-quarter from $34.8 million in Q4 2025.
Amarin Corp Plcuk (AMRN) EBIT (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of EBIT data on file, last reported at -$11.3 million in Q1 2026.
- EBIT for Q1 2026 came in at -$11.3 million, up 32.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.6 million (up 84.03% YoY), and the FY2025 annual result was -$9.0 million, up 53.31% from the prior year.
- EBIT fell to -$11.3 million in Q1 2026 per AMRN's latest filing, from $34.8 million in the prior quarter.
- Over five years, EBIT peaked at $49.3 million in Q4 2023 and troughed at -$62.8 million in Q2 2022.
- A 5-year average of -$9.3 million and a median of -$13.6 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2025: EBIT soared 614.64% in 2023, then tumbled 2950.57% in 2025.
- A 5-year view of EBIT shows it stood at -$9.6 million in 2022, then soared by 614.64% to $49.3 million in 2023, then sank by 59.51% to $20.0 million in 2024, then jumped by 74.38% to $34.8 million in 2025, then slumped by 132.54% to -$11.3 million in 2026.
- Business Quant data shows AMRN's EBIT at -$11.3 million in Q1 2026, $34.8 million in Q4 2025, and -$11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.09 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -182.00 Mn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | -11.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.33 Mn |
| Dec 31, 2025 | 34.83 Mn |
| Sep 30, 2025 | -11.10 Mn |
| Jun 30, 2025 | -15.99 Mn |
| Mar 31, 2025 | -16.76 Mn |
| Dec 31, 2024 | 19.98 Mn |
| Sep 30, 2024 | -25.17 Mn |
| Jun 30, 2024 | -524,000.00 |
| Mar 31, 2024 | -13.58 Mn |
| Dec 31, 2023 | 49.33 Mn |
| Sep 30, 2023 | -21.45 Mn |
| Jun 30, 2023 | -23.96 Mn |
| Mar 31, 2023 | -17.34 Mn |
| Dec 31, 2022 | -9.59 Mn |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -62.83 Mn |
| Mar 31, 2022 | -28.31 Mn |
| Dec 31, 2021 | 8.45 Mn |
| Sep 30, 2021 | -13.07 Mn |
| Jun 30, 2021 | 8.77 Mn |